August 4, 2023 - August 8, 2023

Concord Biotech IPO Review & Recommendations

Choice Equity Broking Pvt Ltd, Hem Securities, HENSEX Securities, LKP Securities Ltd, Motilal Oswal, Reliance Securities, SBICAP Securities Limited and Ventura Securities Limited have given "Apply" recommendation to Concord Biotech IPO. Dilip Davda has given "May Apply" recommendation to Concord Biotech IPO. Capital Market has "Neutral" view about the IPO. Axis Capital, HDFC Securities Limited and JM Financial Institutional Securities have "Not Rated" the IPO.

Concord Biotech IPO Review Summary from brokers and analysts

Review By	Apply	May Apply	Neutral	Avoid	Not Rated
Count	8	1	1	0	3
%	61.54	7.69	7.69	0.00	23.08

Concord Biotech IPO Analysis By Brokers/Analysts

Reviewer	Recommendation	Past Reviews
Axis Capital	Not Rated
Capital Market	Neutral
Choice Equity Broking Pvt Ltd	Apply
Dilip Davda	May Apply
HDFC Securities Limited	Not Rated
Hem Securities	Apply
HENSEX Securities	Apply
JM Financial Institutional Securities	Not Rated
LKP Securities Ltd	Apply
Motilal Oswal	Apply
Reliance Securities	Apply
SBICAP Securities Limited	Apply
Ventura Securities Limited	Apply

Concord Biotech IPO Capital Market Rating

The Captial Market (CapitalMarket.com) rating for Concord Biotech IPO is 44. Their analysis recommends Avoid, however active risk seekers can try for the IPO.

Reviewer	Rating Score	Rating
Capital Market	44	Avoid, however active risk seekers can try

Concord Biotech IPO Review by Dilip Davda (May apply)

[Dilip Davda] The company is an Indian biopharma company with many niche products. It marked a setback in the bottom line for FY22 but posted growth in the top line for the reported three fiscals. Based on FY23 financial performance, the issue appears fully priced. This entire issue is by way of OFS and no fund is going to the company. Well-informed investors may park funds for the medium to long-term rewards. Read detail review...

Concord Biotech IPO Review by Members

Concord Biotech IPO Reviews, analysis and views by popular members. Read Concord Biotech Limited IPO reviews by retail investors to find recommended ipo to buy.

Post Recommendation Manage Your IPO Reviews

Concord Biotech IPO Review Summary by Members

Review By	Apply	May Apply	Neutral	Avoid
Count	7	0	2	3
%	58.33	0.00	16.67	25.00

Member	Review
VANSH PATEL	Avoid I suggest dont apply in this IPO... IPO's will keep come every month, so its better dont invest in every company. Listing gain expectation is very low even in Neutral market. from now till next week many global data comming, if anything comes negative as result and market sentiment gets more worse then it will be definately list in red, now talk about PE... PE is already same as per peers so there also i dont see any listing gain... August 8, 2023 12:21:09 PM
Autouser	Avoid Main reasons for avoiding it.. 1. Complete Offer for Sale.. No Fresh Issue 2. For past last 3 years Revenue is constant / flat 3. Coming to IPO with premium Valuations. 4. Reducing GMP day after day with listing gain scope to 10% to 20% with favorable Market conditions. If something goes other way, expect a Flat/Negative Listing My take: Wait for stock settlement and then purchase directly thru NSE /BSE Even if QIB is more than 50x.. Simply avoid because you will get it much cheaper on exchange August 8, 2023 11:27:39 AM
Dowg Top Contributor (300+ Posts, 100+ Likes)	Apply for Long Term at Upper Price Band 1. Business with reasonable barriers for Fermented APIs 2. Very Good Gross Margins/Oper Margins 3. Nearly Zero Debt Company with High Cash Reserves 4. Reasonable Valuation 5. Big Pipeline of product approvals 6. High chance of allotment August 8, 2023 10:14:09 AM
Rajesh s. IPO Mentor (600+ Posts, 700+ Likes)	Avoid Highly priced, total ofs. My recommendations is to buy 10/15 days after listing. August 7, 2023 10:42:56 PM
Crow IPO Mentor (900+ Posts, 1100+ Likes)	Neutral Concord Biotech has too many red flags for me to give it a "Subscribe" rating. Falling GMP aside, it's a full OFS issue with a P/E and P/B higher than the mean of its legendary peers like Lupin, Divi's, and Aurobindo. There's nothing left on the table also because there's no fancy here. It is possible that the GMP vanishes by listing date, especially in a tricky market that's corrected by about 1% since its July 2023 ATHs. I will apply for 1 retail lot only if QIB crosses 3x on day 3. Thanks. August 4, 2023 7:55:14 PM
Ankit Dhakad	Apply for Long Term at Cut-off Price The financial position is good and borrowings are decreasing YOY. You can apply for longer term. August 4, 2023 5:50:25 PM
B.M.SURANA IPO Guru (2700+ Posts, 5300+ Likes)	Apply for Long Term at Upper Price Band Apply for long-term 2 August 4, 2023 1:29:46 PM
Sbr (200+ Posts)	Apply for Long Term at Cut-off Price LONG TERM IS BEST . August 3, 2023 4:38:14 PM
ASJAD RIZVI	Apply for Long Term at Cut-off Price Looks promising for long term August 1, 2023 8:33:11 PM
Bhupender	Apply for Long Term at Cut-off Price Borrowing are decreasing yoy July 31, 2023 8:07:40 PM
Vaibhva Garodhara	Neutral Profit Ratio has Decreased Due to Purchase of Assets And Repayment Towards Borrowings.But Shareholder Renunciates its Stake Due to So.The ipo is said to be neutral for listing gain And Best For Long term With Risk bearing capacity. July 31, 2023 7:38:02 PM
JAGADISH RATNAKARAM	Apply for Listing Gain at Upper Price Band Subscribe for listing gain 1 July 30, 2023 7:38:24 PM

Post Recommendation Manage Recommendations

Note:

The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
We reserve the right to remove any objectionable post without providing a reason.

2 Comments

2. PearlRohit Link|July 31, 2023 10:29:19 AM

Global Presence. Export More than 70 Country. Year to Year Revenue Growth Positive. FY 2020-21 630+ Cr., FY 2021-22 736+ Cr. & FY 2022-23 888+ Cr & Profit Growth is Positive FY 2020-21 235 Cr, FY 2022-23 240+ Cr. & Main Positive side of Concord Biotech, Company Borrowing is Reduce year to year. Total Borrowing FY 2020-21 Rs. 86.35 Cr., FY 2021-22 Rs. 60.59 Cr. & FY 2022-23 Rs. 31.24 Cr. Very Positive.

1. PearlRohit Link|July 31, 2023 10:21:57 AM

Superb Company. Global Presence. Company has Immunosuppressant (Tacrolimus, Mycophenolate Mofetil) Medicine World Market Share up to Approx 80 to 85 present. World Market Leader for Immunosuppressant Medicine. Company has Own Research Center. Dholka Plant facility is spread over 596,309 square meters & Valthera, Ahmedabad Plant is spread over 94,826 square meters.